Verticals / Pharma, medtech & health distribution / ARS Pharmaceuticals
AP
ARS Pharmaceuticals
arspharma.com ↗—
Latest disclosed NPS
no score published
0
NPS entries
0 with a number
2026
Years covered
1 entries in all
In their words
“ARS Pharmaceuticals posted Q1 2026 revenue of $22.7M with a net retention target of approximately 50%.”
NPS disclosures (0)
No NPS disclosures yet.
Retention disclosures (1)
17 May 2026
Retention50%
ARS Pharmaceuticals posted Q1 2026 revenue of $22.7M with a net retention target of approximately 50%.
— reported by stocktitan.net · 17 May 2026 · NI-5D4AB8D
stocktitan.net ↗Lighthouse companies in Pharma, medtech & health distribution
About these figures
Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.
NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.